Recent studies have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and dopamine signaling. While GLP stimulators are commonly employed for treating type 2 diabetes mellitus, their emerging consequences on reinforcement circuits, specifically media